Publications

Back to staff profile

  • Michael MacManus, R. Fisher, Daniel Roos, Andrew Macann, S. Davis, Richard Tsang, David Christie, Bev McClure, David Joseph, Jayasingham Jayamohan, John F Seymour, Peter O’Brien. Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular Lymphoma: TROG 99.03. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36, 2918-+, 2018. doi: 10.1200/JCO.2018.77.9892.

  • Jolie Ringash, R. Fisher, Lester Peters, Andy Trotti, June Corry, Lizbeth Kenny, Walter Van Den Bogaert, Chris Wratten, Danny Rischin. Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 ( HeadSTART). International Journal of Radiation: Oncology - Biology - Physics, 97, 678-686, 2017. doi: 10.1016/j.ijrobp.2016.03.017.

  • MP Macmanus, R. Fisher, D Roos, A Macann, R Tsang, S. Davis, D Christie, B McClure, D Joseph, JF Seymour. CVP OR R?CVP GIVEN AFTER INVOLVED?FIELD RADIOTHERAPY IMPROVES PROGRESSION FREE SURVIVAL IN STAGE I?II FOLLICULAR LYMPHOMA: RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL. Hematological Oncology, 35, 31, 2017. doi: 10.1002/hon.2437_11.

  • Sue-Anne McLachlan, R. Fisher, John Zalcberg, Michael Solomon, Bryan Burmeister, David Goldstein, Trevor Leong, Stephen P Ackland, Joseph McKendrick, Bev McClure, John Mackay, Samuel Y Ngan, J MacKay. The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). European Journal of Cancer, 55, 15-26, 2016. doi: 10.1016/j.ejca.2015.10.060.

  • Michael A Henderson, Bryan H Burmeister, Jill Ainslie, R. Fisher, Juliana Di Iulio, B Mark Smithers, Angela Hong, Kerwin Shannon, Richard A Scolyer, Scott Carruthers, Brendon J Coventry, Scott Babington, Joao Duprat, Harald J Hoekstra, John F Thompson. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncology, 16, 1049-1060, 2015. doi: 10.1016/S1470-2045(15)00187-4.

  • M Pearse, C Fraser-Browne, ID Davis, G Duchesne, R. Fisher, M Frydenberg, A Haworth, C Jose, DJ Joseph, TS Lim, J Matthews, J Millar, M Sidhom, NA Spry, CI Tang, S Turner, S. Williams, K Wiltshire, HH Woo, A Kneebone. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy - Adjuvant Versus Early Salvage (RAVES) trial. BJU International, 113, 7-12, 2014. doi: 10.1111/bju.12623.

  • MY Lin, M Wu, S Brennan, MP Campeau, DS Binns, M MacManus, B Solomon, RJ Hicks, R. Fisher, DL Ball. Absence of a Relationship between Tumor 18F-fluorodeoxyglucose Standardized Uptake Value and Survival in Patients Treated with Definitive Radiotherapy for Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 9, 377-382, 2014. doi: 10.1097/JTO.0000000000000096.

  • Mateya E Trinkaus, Rodney J Hicks, Richard J Young, Lester J Peters, Ben Solomon, Mathias Bressel, June Corry, R. Fisher, David Binns, Grant A McArthur, Danny Rischin. Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer. Journal of Medical Imaging and Radiation Oncology, 58, 89-97, 2014. doi: 10.1111/1754-9485.12155.

  • DL Ball, R. Fisher, Bev McClure, 90I TROG, TROG 99.05 investigators. Response to dahele and senan. Radiotherapy and Oncology, 109, 180-181, 2013. doi: 10.1016/j.radonc.2013.08.039.

  • DL Ball, R. Fisher, BH Burmeister, MG Poulsen, PH Graham, MG Penniment, SK Vinod, HE Krawitz, DJ Joseph, GC Wheeler, BE McClure. The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: A prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). Radiotherapy and Oncology, 106, 305-311, 2013. doi: 10.1016/j.radonc.2012.12.003.

  • R Young, H Cao, C Kong, E Graves, RJ Hicks, G Mcarthur, L Peters, K Oliner, R. Fisher, A Giaccia, Q Le, D Rischin, Le Quynh-Thu. Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer. Clinical Cancer Research, 18, 1798-1807, 2012. doi: 10.1158/1078-0432.CCR-11-2094.

  • AM Lim, D Rischin, R. Fisher, H Cao, K Kwok, D. Truong, G Mcarthur, R Young, A Giaccia, LJ Peters, Q Le. Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III trial. Clinical Cancer Research, 18, 301-307, 2012. doi: 10.1158/1078-0432.CCR-11-2295.

  • SY Ngan, B Burmeister, R. Fisher, M Solomon, D Goldstein, D Joseph, SP Ackland, D Schache, B McClure, SA McLachlan, J McKendrick, T Leong, C Hartopeanu, J Zalcberg, J Mackay. Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. Journal of Clinical Oncology, 30, 3827-3833, 2012. doi: 10.1200/JCO.2012.42.9597.

  • BH Burmeister, MA Henderson, J Ainslie, R. Fisher, J Di Iulio, BM Smithers, A Hong, K Shannon, RA Scolyer, S Carruthers, BJ Coventry, S Babington, J Duprat, HJ Hoekstra, JF Thompson. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncology, 13, 589-597, 2012. doi: 10.1016/S1470-2045(12)70138-9.

  • D Ball, R. Fisher, B Burmeister, M Poulsen, P Graham, M Penniment, S Vinod, H Krawitz, D Joseph, G Wheeler, B McClure. THE COMPLEX RELATIONSHIP BETWEEN LUNG TUMOR VOLUME AND SURVIVAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED BY DEFINITIVE RADIOTHERAPY: A PROSPECTIVE, OBSERVATIONAL PROGNOSTIC FACTOR STUDY OF THE TRANS-TASMAN RADIATION ONCOLOGY GROUP (TROG 99.05). JOURNAL OF THORACIC ONCOLOGY, 7, S159 (1pp), 2012.

  • Maria Pearse, Andrew Kneebone, Gillian M Duchesne, R. Fisher, Carol Fraser-Browne, Mark Frydenberg, Annette Haworth, Chakiath Jose, David John Joseph, Tee Lim, John Matthews, Jeremy Millar, Mark Sidhom, Nigel Spry, Colin Tang, Sandra Turner, Scott G Williams, Kirsty Wiltshire, Henry Woo, Ian D Davis. What is optimal timing of post prostatectomy radiotherapy? Is adjuvant radiotherapy equivalent to early salvage radiotherapy? The “RAVES” phase III randomized clinical trial.. Journal of Clinical Oncology, 30, TPS4690 (1pp), 2012. doi: 10.1200/jco.2012.30.15_suppl.tps4690.

  • RJ Young, D Rischin, R. Fisher, G Mcarthur, S Fox, LJ Peters, JF Corry, AM Lim, KL Waldeck, B Solomon. Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma. Cancer Epidemiology, Biomarkers & Prevention, 20, 1230-1237, 2011. doi: 10.1158/1055-9965.EPI-10-1262.

  • J Corry, L Peters, R. Fisher, Macann, Jackson, McClure, D Rischin. N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders - Results of Trans Tasman Radiation Oncology Group study 98.02. Head & Neck, 30, 737-742, 2008. doi: 10.1002/hed.20769.

  • D Rischin, R. Fisher, L Peters, J Corry, R Hicks. Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. International Journal of Radiation: Oncology - Biology - Physics, 69, S61-3, 2007. doi: 10.1016/j.ijrobp.2007.05.043.